Form 4: Hologic Director Wayde D. McMillan Reports Acquisition of Stock and Stock Options

Director Wayde D. McMillan reports acquisition of restricted stock units and stock options in Hologic Inc.

Summary

• On April 7, 2025, Wayde D. McMillan, a director of Hologic Inc. (HOLX), reported the acquisition of 1,742 shares of common stock in the form of restricted stock units.
• These restricted stock units vest on the date of the 2026 Annual Meeting of Stockholders and are settled in shares of common stock on a one-for-one basis.
• McMillan also acquired 5,171 non-qualified stock options with an exercise price of $61.27, which become exercisable on the date of the 2026 Annual Meeting of Stockholders and expire on April 7, 2035.
• Following these transactions, McMillan directly owns 1,742 shares of common stock and 5,171 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their alignment with shareholder interests.

Stakeholder Impact

• The acquisition of stock and options by a director can signal confidence in the company's future performance to shareholders.

Key Dates

Keywords

Form 4, Hologic, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, HOLX, Acquisition